v3.26.1
CONSOLIDATED STATEMENT OF LOSS AND OTHER COMPREHENSIVE LOSS - Veraxa Biotech A G [Member] - CHF (SFr)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Entity Information [Line Items]    
Revenue SFr 23,426
Cost of goods sold (7,965)
Gross profit 15,461
General and administrative expenses (46,922,232) (17,095,133)
Research and development expenses (10,264,123) (6,310,608)
Sales and marketing expenses (6,948,456) (3,635,658)
Depreciation and amortization expenses (2,097,225) (1,876,482)
Operating loss (66,216,575) (28,917,881)
Change in fair value of contingent liabilities (799,168) (474,538)
Currency exchange gain (loss) (41,545) 624,154
Other income 54,247 14,811
Finance expenses (3,552) (291)
Loss before taxes (67,006,593) (28,753,745)
Tax benefit 392,603 620,774
Net loss SFr (66,613,990) SFr (28,132,971)
Basic earnings per share SFr (4.60) SFr (2.00)
Diluted earnings per share SFr (4.60) SFr (2.00)
Weighted-average shares outstanding, basic 14,474,974 14,051,547
Weighted-average shares outstanding, diluted 14,474,974 14,051,547
Net loss SFr (66,613,990) SFr (28,132,971)
Foreign operations - currency translation differences (69,022) (222,503)
Total reclassifiable amounts (69,022) (222,503)
Comprehensive Loss SFr (66,683,012) SFr (28,355,474)